Timothy H Chen, MD
Gastroenterology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 3
- Since medical school
- 13 years
- University of Tennessee, Hsc, College of Medicine, 2013
Offices
3 locations · Sutter Bay Medical Foundation · North East Medical Services
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A136216 · Current
Licensed to practise in California · since 2015 · expires 2028-08-31 · University of Tennessee College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$120,089
Medicare paid this office $120,089 for 511 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 174 | $27,111 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 125 | $19,626 | $66 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 92 | $15,169 | $165 |
| Biopsy of large bowel using a flexible endoscope | 138 | $12,102 | $87 |
| Short return visit (20+ min) | 116 | $11,658 | $77 |
See all 10 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 174 | $27,111 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 125 | $19,626 | $66 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 92 | $15,169 | $165 |
| Biopsy of large bowel using a flexible endoscope | 138 | $12,102 | $87 |
| Short return visit (20+ min) | 116 | $11,658 | $77 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 123 | $10,509 | $82 |
| New patient visit (30+ min) | 97 | $9,048 | $93 |
| Diagnostic exam of large bowel using a flexible endoscope | 23 | $3,369 | $146 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $2,494 | $166 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,549 | $103 |
Procedures Medicare counted
| Colonoscopy | 218 | More than 94% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 149 | More than 85% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 63 | 138 | 151 | 167 | 182 | 128 |
| Biopsy of large bowel using a flexible endoscope | 28 | 106 | 114 | 143 | 168 | 139 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | 65 | 64 | 86 | 76 | 92 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | 20 | 18 | 27 | 13 | 23 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | 16 | 13 | 15 | 12 | 15 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | – | 16 | – | – | – | 15 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
511 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 16% · Women 50% · Also on Medicaid 47% · Health risk score 1.61. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 41% · Chronic kidney disease 35% · Coronary heart disease 32% · Atrial fibrillation 27% · Depression 26% · Heart failure 25% · Cancer 19% · COPD 17% · Dementia 17% · Stroke 12%.
The office billed $521,249, Medicare allowed $161,162 and paid $120,089; for 1,209 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 511 | 1,209 | 75 | 1.61 | $521,249 | $120,089 |
| 2023 | 551 | 1,328 | 74 | 1.56 | $560,044 | $139,536 |
| 2022 | 530 | 1,419 | 75 | 1.78 | $577,545 | $147,651 |
| 2021 | 463 | 1,192 | 75 | 1.84 | $484,194 | $132,059 |
| 2020 | 381 | 1,119 | 74 | 1.96 | $444,617 | $122,444 |
| 2019 | 149 | 538 | 75 | 1.84 | $186,704 | $57,738 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 202 | $32,277 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 157 | $22,238 | $70 |
| Biopsy of large bowel using a flexible endoscope | 168 | $16,849 | $100 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 176 | $15,939 | $88 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 76 | $15,653 | $206 |
| New patient visit (30+ min) | 124 | $12,152 | $98 |
| Short return visit (20+ min) | 118 | $11,819 | $79 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,233 | $186 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $1,988 | $153 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,143 | $95 |
2022: 10 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 212 | $38,690 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 164 | $24,788 | $63 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 86 | $16,237 | $189 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 158 | $14,609 | $87 |
| Short return visit (20+ min) | 121 | $13,303 | $77 |
| Biopsy of large bowel using a flexible endoscope | 143 | $12,322 | $86 |
| New patient visit (30+ min) | 108 | $9,348 | $87 |
| Diagnostic exam of large bowel using a flexible endoscope | 27 | $4,105 | $152 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 13 | $2,563 | $197 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,377 | $92 |
2021: 13 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 170 | $32,233 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 130 | $18,303 | $64 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 140 | $14,211 | $94 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 64 | $13,317 | $208 |
| Biopsy of large bowel using a flexible endoscope | 114 | $11,770 | $103 |
| Short return visit (20+ min) | 95 | $10,906 | $83 |
| New patient visit (30+ min) | 102 | $9,581 | $94 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 18 | $3,770 | $209 |
| Diagnostic exam of large bowel using a flexible endoscope | 17 | $2,888 | $160 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 13 | $2,721 | $209 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,288 | $48 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,284 | $99 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 16 | $821 | $51 |
2020: 14 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 150 | $28,380 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 130 | $18,448 | $65 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 64 | $14,313 | $220 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 130 | $13,269 | $96 |
| Biopsy of large bowel using a flexible endoscope | 106 | $12,449 | $117 |
| New patient visit (45+ min) | 61 | $7,944 | $130 |
| Return visit (30+ min) | 46 | $5,115 | $98 |
| Telephone medical discussion with physician, 11-20 minutes | 63 | $4,388 | $54 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $3,101 | $155 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $2,575 | $161 |
| Short return visit (20+ min) | 30 | $2,220 | $67 |
| New patient visit (30+ min) | 18 | $1,832 | $102 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,640 | $103 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 21 | $1,078 | $51 |
2019: 10 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $14,710 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 79 | $13,719 | $64 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 60 | $6,093 | $97 |
| New patient visit (45+ min) | 30 | $4,526 | $151 |
| Biopsy of large bowel using a flexible endoscope | 28 | $3,238 | $116 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | $2,860 | $220 |
| Return visit (30+ min) | 24 | $2,435 | $101 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $2,182 | $168 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,402 | $100 |
| Short return visit (20+ min) | 14 | $975 | $70 |
Medicaid work
$101,101 in 2024
Medicaid paid $101,101 for 1,813 billed services this clinician did in 2024, up to 55 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 385 | $62,866 |
| 1ST HOSP IP/OBS HIGH 75 | 98 | $14,112 |
| Upper gastrointestinal endoscopy with biopsy | 180 | $11,953 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 98 | $5,775 |
| COLONOSCOPY AND BIOPSY | 198 | $3,931 |
| COLONOSCOPY W/LESION REMOVAL | 57 | $2,092 |
| Short return visit | 652 | $372 |
| Service | 145 | $0 |
| 2024 | 1,813 | 8 | 55 | $101,101 |
| 2023 | 2,102 | 10 | 41 | $88,304 |
| 2022 | 1,356 | 7 | 38 | $51,683 |
| 2021 | 1,191 | 7 | 38 | $46,388 |
| 2020 | 858 | 8 | 33 | $41,355 |
| 2019 | 110 | 2 | 21 | $3,937 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 398 | $58,937 |
| 1ST HOSP IP/OBS HIGH 75 | 71 | $10,986 |
| Upper gastrointestinal endoscopy with biopsy | 247 | $8,757 |
| COLONOSCOPY AND BIOPSY | 323 | $4,054 |
| COLONOSCOPY W/LESION REMOVAL | 46 | $3,230 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 38 | $1,885 |
| Short return visit (20+ min) | 12 | $300 |
| Short return visit | 760 | $154 |
| Service | 169 | $0 |
| BODY MASS INDEX DOCD | 38 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 246 | $35,582 |
| 1ST HOSP IP/OBS HIGH 75 | 49 | $5,685 |
| Upper gastrointestinal endoscopy with biopsy | 154 | $5,409 |
| COLONOSCOPY AND BIOPSY | 126 | $3,529 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 27 | $952 |
| COLONOSCOPY W/LESION REMOVAL | 30 | $418 |
| Short return visit | 724 | $108 |
2021
| Clinic visit/encounter, all-inclusive | 230 | $32,452 |
| Upper gastrointestinal endoscopy with biopsy | 148 | $5,470 |
| 1ST HOSP IP/OBS HIGH 75 | 29 | $3,936 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 67 | $2,621 |
| COLONOSCOPY AND BIOPSY | 85 | $1,754 |
| Short return visit | 620 | $155 |
| COLONOSCOPY W/LESION REMOVAL | 12 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 210 | $30,303 |
| Upper gastrointestinal endoscopy with biopsy | 49 | $4,449 |
| COLONOSCOPY AND BIOPSY | 65 | $3,973 |
| 1ST HOSP IP/OBS HIGH 75 | 24 | $2,438 |
| New patient visit (30+ min) | 162 | $98 |
| Short return visit | 321 | $93 |
| COLONOSCOPY W/LESION REMOVAL | 14 | $0 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 13 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 28 | $3,883 |
| New patient visit (30+ min) | 82 | $54 |
Drugs they prescribed that Part D paid
$356,110
Pharmacies billed $356,110 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 993) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
802 generic and 191 brand-name prescriptions · $356,110 in drug cost · 51 antibiotic prescriptions to 25 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vemlidy | 20 | $54,823 | $2,741 |
| Creon | 17 | $39,644 | $2,332 |
| Linzess | 13 | $16,301 | $1,254 |
| Mesalamine | 15 | $10,122 | $675 |
| Sod Sulf-Potass Sulf-Mag Sulf | 121 | $7,727 | $64 |
See all 16 drugs
| Vemlidy | 20 | $54,823 | $2,741 |
| Creon | 17 | $39,644 | $2,332 |
| Linzess | 13 | $16,301 | $1,254 |
| Mesalamine | 15 | $10,122 | $675 |
| Sod Sulf-Potass Sulf-Mag Sulf | 121 | $7,727 | $64 |
| Pantoprazole | 279 | $4,974 | $18 |
| Tetracycline | 19 | $4,171 | $220 |
| Mesalamine Er | 14 | $3,922 | $280 |
| Sucralfate | 19 | $3,526 | $186 |
| Gavilyte-C | 174 | $2,513 | $14 |
| Entecavir | 13 | $1,909 | $147 |
| Famotidine | 67 | $1,024 | $15 |
| Dicyclomine | 15 | $842 | $56 |
| Gavilyte-G | 22 | $300 | $14 |
| Omeprazole | 37 | $212 | $6 |
| Metronidazole | 24 | $152 | $6 |
Year by year
| 2024 | 993 | 521 | 0% (0) | 19% | $356,110 |
| 2023 | 888 | 449 | 0% (0) | 20% | $326,282 |
| 2022 | 809 | 412 | 0% (0) | 36% | $311,385 |
| 2021 | 811 | 375 | 0% (0) | 43% | $179,425 |
| 2020 | 557 | 260 | 0% (0) | 41% | $95,225 |
| 2019 | 139 | 84 | 0% (0) | 34% | $15,447 |
| 2018 | 47 | 15 | 0% (0) | None | $107,715 |
| 2017 | 57 | 30 | 0% (0) | None | $10,081 |
| 2016 | 37 | 20 | 0% (0) | None | $1,505 |
| 2014 | 17 | None | 0% (0) | None | $584 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Vemlidy | 18 | $44,792 | $2,488 |
| Creon | 17 | $40,483 | $2,381 |
| Mesalamine | 25 | $14,104 | $564 |
| Mesalamine Er | 20 | $7,274 | $364 |
| Pantoprazole | 254 | $6,821 | $27 |
| Sod Sulf-Potass Sulf-Mag Sulf | 72 | $5,399 | $75 |
| Gavilyte-C | 160 | $3,144 | $20 |
| Tetracycline | 16 | $2,982 | $186 |
| Suprep | 19 | $2,281 | $120 |
| Famotidine | 62 | $1,572 | $25 |
| Gavilyte-G | 49 | $845 | $17 |
| Omeprazole | 26 | $382 | $15 |
| Metronidazole | 16 | $137 | $9 |
2022: 16 drugs
| Suprep | 115 | $13,539 | $118 |
| Mesalamine Er | 27 | $12,566 | $465 |
| Mesalamine | 25 | $12,164 | $487 |
| Apriso | 12 | $5,595 | $466 |
| Plenvu | 34 | $4,736 | $139 |
| Pantoprazole | 231 | $4,010 | $17 |
| Sod Sulf-Potass Sulf-Mag Sulf | 11 | $888 | $81 |
| Gavilyte-C | 48 | $819 | $17 |
| Famotidine | 48 | $543 | $11 |
| Dicyclomine | 11 | $504 | $46 |
| Clarithromycin | 12 | $470 | $39 |
| Gavilyte-G | 20 | $272 | $14 |
| Peg-3350 and Electrolytes | 20 | $249 | $12 |
| Omeprazole | 16 | $225 | $14 |
| Metronidazole | 20 | $224 | $11 |
| Amoxicillin | 11 | $119 | $11 |
2021: 16 drugs
| Vemlidy | 15 | $46,535 | $3,102 |
| Mesalamine Er | 39 | $19,684 | $505 |
| Suprep | 170 | $18,901 | $111 |
| Mesalamine | 24 | $16,699 | $696 |
| Linzess | 21 | $14,940 | $711 |
| Motegrity | 13 | $8,895 | $684 |
| Pantoprazole | 207 | $4,869 | $24 |
| Plenvu | 28 | $3,621 | $129 |
| Sucralfate | 23 | $2,049 | $89 |
| Dicyclomine | 22 | $1,006 | $46 |
| Entecavir | 11 | $776 | $71 |
| Famotidine | 40 | $647 | $16 |
| Omeprazole | 33 | $570 | $17 |
| Clarithromycin | 14 | $402 | $29 |
| Metronidazole | 19 | $200 | $11 |
| Amoxicillin | 14 | $142 | $10 |
2020: 11 drugs
| Suprep | 134 | $14,111 | $105 |
| Linzess | 13 | $8,856 | $681 |
| Motegrity | 12 | $7,322 | $610 |
| Dexilant | 11 | $6,371 | $579 |
| Pantoprazole | 138 | $2,533 | $18 |
| Omeprazole | 58 | $975 | $17 |
| Sucralfate | 21 | $863 | $41 |
| Clarithromycin | 11 | $601 | $55 |
| Famotidine | 13 | $202 | $16 |
| Metronidazole | 17 | $182 | $11 |
| Amoxicillin | 11 | $133 | $12 |
2019: 3 drugs
| Suprep | 34 | $3,393 | $100 |
| Pantoprazole | 22 | $541 | $25 |
| Omeprazole | 21 | $479 | $23 |
Money from drug and device companies
$2,605 in 2025
| 2025 | 17 | 115 | None | $2,605 |
| 2024 | 21 | 74 | None | $1,898 |
| 2023 | 17 | 95 | None | $1,749 |
| 2022 | 13 | 79 | None | $1,388 |
| 2021 | 8 | 54 | None | $759 |
| 2020 | 8 | 41 | None | $518 |
| 2019 | 8 | 20 | None | $517 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $687 | 33 payments
|
| Janssen Biotech | Tremfya | $427 | 16 payments
|
| Aimmune Therapeutics | Zenpep | $275 | 10 payments
|
| Lilly USA | Omvoh | $225 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $195 | 15 payments
|
| Pfizer | Xeljanz | $110 | 5 payments
|
See all 115 published payments
| Janssen Biotech | Meals · 2025-12-23 | Tremfya | $21 |
| Phathom Pharmaceuticals | Meals · 2025-12-23 | Voquezna | $4 |
| Phathom Pharmaceuticals | Meals · 2025-12-21 | Voquezna | $4 |
| Abbvie | Meals · 2025-12-17 | Skyrizi | $31 |
| QOL Medical | Meals · 2025-12-16 | Sucraid | $27 |
| Celltrion USA | Meals · 2025-12-16 | Vegzelma | $23 |
| Janssen Biotech | Meals · 2025-12-10 | Tremfya | $24 |
| Abbvie | Meals · 2025-12-09 | Creon | $8 |
| Aimmune Therapeutics | Meals · 2025-12-08 | Zenpep | $34 |
| Aimmune Therapeutics | Meals · 2025-12-04 | Zenpep | $27 |
| Aimmune Therapeutics | Meals · 2025-11-21 | Zenpep | $32 |
| Abbvie | Meals · 2025-11-15 | Creon | $16 |
| Regeneron Healthcare Solutions | Meals · 2025-11-13 | Dupixent | $34 |
| Aimmune Therapeutics | Meals · 2025-11-12 | Zenpep | $33 |
| Janssen Biotech | Meals · 2025-11-11 | Tremfya | $9 |
| Novo Nordisk | Meals · 2025-11-11 | Wegovy | $21 |
| Novo Nordisk | Meals · 2025-11-05 | Wegovy | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-04 | Entyvio | $7 |
| Abbvie | Meals · 2025-11-03 | Linzess | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-03 | Entyvio | $3 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-30 | Entyvio | $29 |
| Abbvie | Meals · 2025-10-28 | Linzess | $15 |
| Madrigal Pharmaceuticals | Meals · 2025-10-28 | Rezdiffra | $26 |
| Janssen Biotech | Meals · 2025-10-27 | Tremfya | $8 |
| Abbvie | Meals · 2025-10-22 | Rinvoq | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-21 | Entyvio | $8 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-21 | Entyvio | $15 |
| Phathom Pharmaceuticals | Meals · 2025-10-20 | Voquezna | $12 |
| Janssen Biotech | Meals · 2025-10-15 | Tremfya | $27 |
| Novo Nordisk | Meals · 2025-10-15 | Wegovy | $20 |
| Janssen Biotech | Meals · 2025-10-13 | Tremfya | $8 |
| QOL Medical | Meals · 2025-10-13 | Sucraid | $26 |
| Abbvie | Meals · 2025-10-07 | Linzess | $26 |
| Abbvie | Meals · 2025-09-26 | Linzess | $17 |
| Phathom Pharmaceuticals | Meals · 2025-09-25 | Voquezna | $30 |
| Celltrion USA | Meals · 2025-09-23 | Vegzelma | $29 |
| Regeneron Healthcare Solutions | Meals · 2025-09-22 | Dupixent | $38 |
| Phathom Pharmaceuticals | Meals · 2025-09-16 | Voquezna | $25 |
| Abbvie | Meals · 2025-09-10 | Rinvoq | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-08 | Entyvio | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-08 | Entyvio | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-08 | Entyvio | $10 |
| Aimmune Therapeutics | Meals · 2025-09-08 | Vowst | $27 |
| Abbvie | Meals · 2025-09-02 | Skyrizi | $27 |
| Abbvie | Meals · 2025-08-21 | Creon | $8 |
| Pfizer | Meals · 2025-08-20 | Xeljanz | $19 |
| Braintree Laboratories | Meals · 2025-08-19 | Sutab | $25 |
| Lilly USA | Meals · 2025-08-13 | Omvoh | $32 |
| Ipsen Biopharmaceuticals | Meals · 2025-08-06 | Iqirvo | $22 |
| Aimmune Therapeutics | Meals · 2025-08-04 | Zenpep | $15 |
| Aimmune Therapeutics | Meals · 2025-08-04 | Zenpep | $16 |
| Abbvie | Meals · 2025-07-28 | Linzess | $26 |
| Celltrion USA | Meals · 2025-07-28 | Vegzelma | $23 |
| Aimmune Therapeutics | Meals · 2025-07-16 | Zenpep | $31 |
| Janssen Biotech | Education · 2025-07-14 | Tremfya | $85 |
| Lilly USA | Meals · 2025-07-10 | Omvoh | $31 |
| Abbvie | Meals · 2025-07-09 | Creon | $8 |
| Janssen Biotech | Meals · 2025-07-08 | Tremfya | $17 |
| Aimmune Therapeutics | Meals · 2025-06-25 | Zenpep | $36 |
| LivaNova USA | Meals · 2025-06-24 | Vns Therapy Sentiva Model 1000 Generator | $21 |
| Lilly USA | Meals · 2025-06-16 | Omvoh | $35 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-16 | Entyvio | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-16 | Entyvio | $8 |
| Gilead Sciences | Meals · 2025-06-16 | None | $18 |
| Abbvie | Meals · 2025-06-11 | Rinvoq | $21 |
| Braintree Laboratories | Meals · 2025-06-10 | Sutab | $24 |
| Abbvie | Meals · 2025-06-06 | Rinvoq | $31 |
| Abbvie | Meals · 2025-06-05 | Skyrizi | $29 |
| Abbvie | Meals · 2025-06-04 | Rinvoq | $30 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-28 | Eohilia | $25 |
| Abbvie | Meals · 2025-05-27 | Rinvoq | $18 |
| Lilly USA | Meals · 2025-05-21 | Omvoh | $30 |
| Pfizer | Meals · 2025-05-16 | Xeljanz | $24 |
| Abbvie | Meals · 2025-05-07 | Rinvoq | $20 |
| Abbvie | Meals · 2025-05-01 | Rinvoq | $30 |
| Abbvie | Meals · 2025-04-30 | Rinvoq | $21 |
| Aimmune Therapeutics | Meals · 2025-04-29 | Zenpep | $24 |
| Phathom Pharmaceuticals | Meals · 2025-04-28 | Voquezna | $22 |
| Abbvie | Meals · 2025-04-22 | Rinvoq | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-22 | Entyvio | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-18 | Entyvio | $11 |
| Pfizer | Meals · 2025-04-17 | Xeljanz | $19 |
| Janssen Biotech | Meals · 2025-04-16 | Tremfya | $26 |
| Abbvie | Meals · 2025-04-16 | Creon | $13 |
| Gilead Sciences | Meals · 2025-04-15 | None | $14 |
| Abbvie | Meals · 2025-04-12 | Rinvoq | $26 |
| Lilly USA | Meals · 2025-04-09 | Omvoh | $30 |
| Braintree Laboratories | Meals · 2025-04-08 | Sutab | $28 |
| Janssen Biotech | Meals · 2025-04-07 | Tremfya | $21 |
| Janssen Biotech | Meals · 2025-03-26 | Tremfya | $25 |
| Janssen Biotech | Meals · 2025-03-24 | Tremfya | $13 |
| Lilly USA | Meals · 2025-03-12 | Omvoh | $33 |
| Madrigal Pharmaceuticals | Meals · 2025-03-10 | Rezdiffra | $34 |
| Pfizer | Meals · 2025-03-05 | Xeljanz | $24 |
| Abbvie | Meals · 2025-03-04 | Skyrizi | $34 |
| Abbvie | Meals · 2025-03-01 | Linzess | $27 |
| Janssen Biotech | Meals · 2025-02-26 | Tremfya | $38 |
| Boston Scientific | Meals · 2025-02-22 | Captivator II | $38 |
| Boston Scientific | Meals · 2025-02-22 | Captivator II | $21 |
| Janssen Biotech | Meals · 2025-02-21 | Tremfya | $43 |
| Abbvie | Meals · 2025-02-21 | Skyrizi | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-20 | Entyvio | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-02-12 | Dupixent | $36 |
| Pfizer | Meals · 2025-02-12 | Xeljanz | $24 |
| Celltrion USA | Meals · 2025-02-11 | Vegzelma | $20 |
| Abbvie | Meals · 2025-02-04 | Creon | $6 |
| Lilly USA | Meals · 2025-01-30 | Omvoh | $35 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-27 | Entyvio | $23 |
| Abbvie | Meals · 2025-01-23 | Rinvoq | $21 |
| Janssen Biotech | Meals · 2025-01-15 | Tremfya | $32 |
| Abbvie | Meals · 2025-01-14 | Creon | $24 |
| Abbvie | Meals · 2025-01-14 | Creon | $1 |
| Abbvie | Meals · 2025-01-08 | Rinvoq | $19 |
| Abbvie | Meals · 2025-01-07 | Creon | $18 |
| Janssen Biotech | Meals · 2025-01-02 | Tremfya | $30 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,898
| Janssen Biotech | Tremfya | $362 | 12 payments
|
| Abbvie | Rinvoq | $291 | 14 payments
|
| Medtronic | Endoflip | $132 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $126 | 5 payments
|
| Pfizer | Xeljanz | $117 | 6 payments
|
| Ironwood Pharmaceuticals | Linzess | $114 | 5 payments
|
| Merck Sharp & Dohme | Dificid | $98 | 4 payments
|
| Celltrion USA | Vegzelma | $84 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $75 | 2 payments
|
| Gilead Sciences | None | $70 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $68 | 3 payments
|
| Lilly USA | Omvoh | $66 | 2 payments
|
| Madrigal Pharmaceuticals | Resmetirom | $46 | 2 payments
|
| Phathom Pharmaceuticals | Voquezna | $42 | 2 payments
|
| Genzyme | Dupixent | $42 | 1 payment
|
| QOL Medical | Sucraid | $39 | 2 payments
|
| Celgene | Zeposia | $35 | 2 payments
|
| Fresenius Kabi USA | Idacio | $33 | 1 payment
|
| Aimmune Therapeutics | Zenpep | $24 | 1 payment
|
| Ipsen Biopharmaceuticals | Iqirvo | $19 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $16 | 1 payment
|
2023: $1,749
| AbbVie | Skyrizi | $512 | 30 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $311 | 17 payments
|
| Janssen Biotech | Stelara | $276 | 19 payments
|
| Merck Sharp & Dohme | Dificid | $119 | 5 payments
|
| Pfizer | Xeljanz | $111 | 5 payments
|
| Regeneron Healthcare Solutions | Dupixent | $63 | 2 payments
|
| Gilead Sciences | None | $56 | 2 payments
|
| Ferring Pharmaceuticals | Rebyota | $53 | 3 payments
|
| Nestle Healthcare Nutrition | Zenpep | $50 | 2 payments
|
| Ironwood Pharmaceuticals | Linzess | $49 | 3 payments
|
| Intercept Pharmaceuticals | Ocaliva | $23 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $22 | 1 payment
|
| Amgen | Amjevita | $22 | 1 payment
|
| Genzyme | Dupixent | $22 | 1 payment
|
| QOL Medical | Sucraid | $20 | 1 payment
|
| Fresenius Kabi USA | Idacio | $20 | 1 payment
|
| RedHill Biopharma | Talicia | $18 | 1 payment
|
2022: $1,388
| Abbvie | Rinvoq | $553 | 36 payments
|
| Janssen Biotech | Stelara | $311 | 23 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $117 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $100 | 4 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $55 | 3 payments
|
| Merck Sharp & Dohme | Dificid | $50 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $39 | 2 payments
|
| Medtronic | Gi Genius | $37 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $35 | 2 payments
|
| Nestle HealthCare Nutrition | Zenpep | $28 | 1 payment
|
| Amgen | Avsola | $25 | 1 payment
|
| Evoke Pharma | Gimoti | $20 | 1 payment
|
| RedHill Biopharma | Talicia | $18 | 1 payment
|
2021: $759
| AbbVie | Humira | $355 | 23 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $142 | 14 payments
|
| Janssen Biotech | Stelara | $116 | 9 payments
|
| Ironwood Pharmaceuticals | Linzess | $53 | 3 payments
|
| Gilead Sciences | None | $42 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $25 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $14 | 1 payment
|
| Braintree Laboratories | Sutab | $11 | 1 payment
|
2020: $518
| AbbVie | Humira | $183 | 11 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $165 | 21 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $56 | 2 payments
|
| Janssen Biotech | Remicade | $36 | 2 payments
|
| Ferring Pharmaceuticals | Clenpiq | $27 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $19 | 1 payment
|
| Alfasigma USA | None | $19 | 1 payment
|
| Gilead Sciences | None | $13 | 1 payment
|
2019: $517
| Ironwood Pharmaceuticals | Linzess | $125 | 3 payments
|
| Allergan | Avycaz | $125 | 1 payment
|
| AbbVie | Creon | $88 | 4 payments
|
| Merck Sharp & Dohme | Dificid | $78 | 5 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $50 | 3 payments
|
| Janssen Biotech | Remicade | $24 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Motegrity | $15 | 2 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $12 | 1 payment
|
Professional record
- NPI
- 1699017707
- Licence
- CA A136216California A136216: Current · expires 2028-08-31
- Trained
- University of Tennessee, Hsc, College of Medicine, 2013 · 13 years ago
- Group
- Sutter Bay Medical Foundation · North East Medical Services
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 2100 Webster St Ste 115, San Francisco, CA, 94115
- NPI first listed
- 2013-03-27
- NPI last updated
- 2022-02-14
- NPI record certified
- 2022-02-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2100 Webster St Ste 516, San Francisco, CA, 94115 · 3801 Sacramento St Ste 300, San Francisco, CA, 94118